BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/16/2020 7:58:40 AM | Browse: 1065 | Download: 2128
 |
Received |
|
2019-11-23 07:19 |
|
Peer-Review Started |
|
2019-11-23 07:19 |
|
First Decision by Editorial Office Director |
|
2019-12-23 14:08 |
|
Return for Revision |
|
2019-12-23 14:08 |
|
Revised |
|
2020-01-07 11:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-01-09 09:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-01-11 14:04 |
|
Articles in Press |
|
2020-01-11 14:04 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-01-13 14:02 |
|
Publish the Manuscript Online |
|
2020-01-16 07:58 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Takumi Onoyama, Yohei Takeda, Taro Yamashita, Wataru Hamamoto, Yuri Sakamoto, Hiroki Koda, Soichiro Kawata, Kazuya Matsumoto and Hajime Isomoto |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Takumi Onoyama, MD, PhD, Doctor, Doctor, Department of Multidisciplinary Internal Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Tottori prefecture, Japan. golf4to@yahoo.co.jp |
| Key Words |
Nivolumab; Pembrolizumab; Avelumab; Durvalumab; Atezolizumab; Programmed cell death-1 inhibitor |
| Core Tip |
This study systematically reviewed the literature on the programmed cell death-1 inhibitor-related sclerosing cholangitis. Biliary dilation without obstruction, diffuse hypertrophy of the extrahepatic biliary tract and/or multiple strictures of intrahepatic biliary tract, liver dysfunction with a notable increase in biliary tract enzymes relative to hepatic enzymes, normal level of the serum immunoglobulin G4, and a moderate to poor response to steroid therapy, and CD8+ T cell infiltration in the biliary tract were clinical and pathological features of programmed cell death-1 inhibitor-related sclerosing cholangitis. |
| Publish Date |
2020-01-16 07:58 |
| Citation |
Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i3/353.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i3.353 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
